Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Current facts and the real truth about this dumpster stock:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174449573
You do realize that those "those debt converted preferred shares" go to BONAR and his family to pay for the family businesses like DepCo bought by DFCO, don't you?
Then when DFCO goes bust they get the business back anyhow.
Do your own DD... geez.....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174439196
Too funny !!!!!
I firmly believe that MM’s are shorting it. None of the big guys but a bunch of traders who are borrowing stock to cover there short.
05/17/24 0.1941 0.1997 0.181 0.181 27,253
05/16/24 0.181 0.197 0.181 0.197 20,595
05/15/24 0.198 0.198 0.181 0.1855 8,197
05/14/24 0.213 0.213 0.191 0.198 112,686
05/13/24 0.197 0.197 0.186 0.1959 26,949
05/10/24 0.1899 0.197 0.1899 0.197 6,206
05/09/24 0.197 0.197 0.19 0.19 30,328
05/08/24 0.186 0.19 0.186 0.19 6,120
05/07/24 0.181 0.19 0.181 0.19 1,178
05/06/24 0.1906 0.1906 0.1846 0.1846 10,240
05/03/24 0.1945 0.1962 0.185 0.185 26,204
05/02/24 0.196 0.1965 0.189 0.195 12,916
05/01/24 0.1928 0.1997 0.1928 0.1997 7,113
04/30/24 0.188 0.20 0.188 0.1969 53,295
04/29/24 0.19 0.20 0.188 0.1922 71,491
Again, if this was other stock with this type financial report it would be $1 $5 now. I saw stock smaller revenue and is trading $5.
Mm is and had been doing this since the stock was at .01s I've been through it all. For an example the other days 51k was bought at .213 but yet the stock ended up down on 5k selling... I even put in big order and got filled then it would go.back down with 1k 4k shares. I was buying big blocks of it months ago at .15s for days then after a month mm let's it go to .234 was the highest then he decided to pulled the plug. With little or no volume at all. That mm shorting, I don't care what naysers..
Interestingly I saw last Friday an additional 3 mills were added to outstanding shares, anyone looked into that? Seemed like every qtr those debt converted preferred shares a d onto outstanding shares.. Now total os is 63mills. What ya take on that?
Leave her on ignore. If she stuck to CURRENT facts and stopped the personal attacks on the CEO then maybe I would take her input under consideration. The way she behaves is simply a personal attack on a man and nothing to do with the company. Pretty sad.
I firmly believe that MM’s are shorting it. None of the big guys but a bunch of traders who are borrowing stock to cover there short. I am going to reach out to the company tomorrow to see if they have an explanation or a plan to squeeze them. As I have said before even on a one time multiple of sales this stock today should be between .40c to .60c. Will advise the what I find out.
U.S. Courts don't believe Brian Bonar, why should you?
See replied to post and this:
Hon. Janis L. Sammartino, United States District Judge
ORDER GRANTING IN PART AND DENYING IN PART PLAINTIFFS' MOTION FOR LEAVE TO SERVE SUMMONS AND COMPLAINT BY ALTERNATIVE OR SUBSTITUTED SERVICE AND REQUEST FOR EXTENSION OF TIME FOR SERVICE OF PROCESS (ECF NOS. 9, 10)
Hon. Janis L. Sammartino, United States District Judge
Presently before the Court are Plaintiffs Dalrada Precision Corporation and Dalrada Financial Corporation's (collectively, “Plaintiffs”) Opposition to Motion to Dismiss Complaint (“Opp'n,” ECF No. 10) and Motion for Leave to Serve Summons and Complaint by Alternative or Substituted Service and Request for Extension of Time for Service of Process (“Mot.,” ECF No. 9).
In its June 29, 2023 Order (“Order,” ECF No. 7), which the Court here incorporates by reference, the Court denied Plaintiffs' requests for a temporary restraining order and preliminary injunction. In the six months following the Order, no action occurred in the case. The Court therefore set this matter for hearing on February 9, 2024 pursuant to Civil Local Rule 41.1, which allows the Court to dismiss an action pending for six months or more without action for want of prosecution. See ECF No. 8. Plaintiffs responded to this Court's Notice of Hearing by filing the Motion and Opposition on February 5, 2024.
Plaintiffs explain that the delay in this case relates to their inability to serve Defendant Stuart Cox, who “currently resides in the Philippines.” Opp'n at 4. Though Plaintiffs possess an email address and cell number for Defendant, they lack any “location information for Defendant other than a region/area where he is believed to be residing.” Id. Plaintiffs report they have conducted “an exhaustive internet search such as Google, Linkdin [sic], etc.” that failed to uncover an address for Defendant. Id. Plaintiffs also indicate they have recently engaged an international company to “perform a skip trace on Defendant in order to find a location where he could be served.” Id. Plaintiffs request that the Court (1) provide “leave to serve Defendant . . . by publication in an adjudicated newspaper where Defendant was last known to have resided” and (2) “grant . . . an extension of time in which to serve Defendant.” Mot. at 5.
As Plaintiffs have not made a sufficient showing to justify service by publication on an individual residing in a foreign country, the Court DENIES WITHOUT PREJUDICE Plaintiffs' request to serve Defendant by publication. Plaintiffs-who are represented by counsel-argue that the Court may authorize service by publication pursuant to Federal Rule of Civil Procedure 4(e)(1) and California law. See Mot. at 3 (citing Cal. Civ. Proc. Code § 415.50). But Rule 4(e) governs service on “an individual . . . in a judicial district of the United States.” Fed.R.Civ.P. 4(e). It is Rule 4(f), not Rule 4(e), that governs service on individuals within a foreign country. Fed.R.Civ.P. 4(f). Plaintiffs make no argument as to whether Rule 4(f) authorizes service by publication under the circumstances of this case, and the Court will not manufacture arguments for Plaintiffs.
Even if Rule 4(e)-and through it, California law-applied, Plaintiffs' showing would be insufficient. California Code of Civil Procedure § 415.50 requires Plaintiffs to submit “affidavit[s]” demonstrating, among other required showings, that service cannot be completed through reasonable diligence by means other than publication. Though Plaintiffs' Motion references “declarations attached hereto,” Mot. at 3, Plaintiffs filed no declaration or affidavit alongside either their Motion or Opposition describing their efforts to locate and serve Defendant. Moreover, as Plaintiffs have neither completed a skip trace nor explained the approximately four-month gap between when they first requested a quote for a skip trace on Defendant and when their current skip trace allegedly commenced, see Opp'n Ex. A at 1-2, the Court is skeptical that Plaintiffs have exercised reasonable diligence in their efforts to locate and serve Defendant up to this point, see United Fin. Cas. Co. v. R.U.R. Transportation, Inc., No. 22CV333-LL-WVG, 2022 WL 16747283, at *3-4 (S.D. Cal. Nov. 7, 2022) (finding reasonable diligence in part because an investigator's completed skip trace had not located the defendant). Lastly, Plaintiffs have not identified through which publication they intend to serve Defendant nor explained why said publication is likely to provide notice to Defendant. See id. at *5.
Sing to the music of the "Mr Ed" theme song...
https://www.google.com/search?q=midter+ed+theme+song+audio&rlz=1C1ONGR_enUS1087US1087
The lyrics:
DFCO isn't a stock that you'd endorse...
You'll get no answer but total B.S.
Bonar's always on a crooked course.
He's a famous stock market con.
I saw that there 3 mills added to outstanding shares, maybe this is why we dropped under .20 from .22 .23 for a week and there were some huge volume for 3 days from the dropped. And naked shorting also on this stock. With the financial report so good and the stock didn't move then you know a lot of manipulation going on..Like I said until this naked shorting and mm working together with whomever it is then we're not going anywhere and only frustrating those longs and that's their intention by forcing them to sell their positions out of frustration..
How can you have "confidence in your DD" when there is no unique IP, no patents, and no coherent business plan?
Anyone who isn't aware of the above hasn't done "DD".
You're wrong - my vendetta is with stock market crooks in general.
BONAR may be the greatest living example of this.
She still add it...lol...I have her on ignore...I cant handle the drug induced BS...
Float is all locked up with strong longs - only when the shorts begin to cover this will make a huge run up - until then just holding what I have and waiting for the $5 Nasdaq buyout :D $DFCO
Been holding since $.02 and not going anywhere - no matter how much BS and lies Xena posts lol she already acknowledge that the only reason she’s here is a vendetta agains Bonar - not the company - piece of work lol it’s a pity dedicating your life to bash one person - really a waste
In my opinion this isn't so much shorting then just a pure lack of interest. Having said that the whole OTC market is s a bit slow, as I said the other day a ton of risk capital has moved to crypto, will those monies come back to the OTC....sure, when, I have no idea. DFCO isn't just a heat pump maker, they're a holding company with multiple revenue models. DFCO has to be clear on the branding of the company and explain the business model, I believe they're heading in the right direction. I have a very large position in DFCO, I'm staying in for the long term, we're not going to sell a company just because it's not moving today, have confidence in your DD, and stay the path unless proven otherwise.
What's wrong with this picture????
Shareholder Letter from Chairman and CEO, Brian Bonar
February 9, 2024
Dalrada ($DFCO) announced today that it had filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC), in which company Chairman and CEO, Brian Bonar, penned an open letter to the company’s shareholders. In it, he describes some of the past year’s major accomplishments and offers a look ahead at 2024. Read the letter below:
I would like to take this time to address our valued shareholders about the events of 2023 and our expectations for 2024. I will share how two of our leading businesses —within the healthcare and climate technology sectors—formed a solid foundation for Dalrada’s overall progress and success not just in 2023, but beyond.
As I reflect on the positive results and milestones we achieved in 2023, I realize that it was quite a transformative year for Dalrada. Not only did the company continue its successive quarterly revenue growth, but at the close of the fiscal year, Dalrada saw an impressive 54.3% revenue increase from the prior year. Increased revenues totaled approximately $30 million, which was $10 million more than the 2022 fiscal year.
On behalf of the Dalrada team, I would like to thank each and every shareholder for your continued support as we enact our vision and strategy to bring continued success to our organization.
Brian Bonar
Dalrada’s CEO and Founder/quote]
Dalrada Technology Ltd. Moves into New UK Headquarters Designated for Clean Energy Technology and Manufacturing
New facility will allow the specialized division of Dalrada Financial Corporation to further expand Deposition Technology (DepTec) and Likido
February 09, 2023 08:00 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”), announced today that its UK division, Dalrada Technology Ltd., has signed a 10-year lease agreement at a new warehouse and office facility where it will continue to focus its efforts on driving clean energy technology and manufacturing advancements.
Dalrada Technology Ltd. intends to make the 20,000-square foot unit in Livingston, Scotland, its new UK headquarters, designating it for the manufacture of clean energy and semiconductor manufacturing technologies. To achieve this, the new facility will incorporate two wholly-owned Dalrada Corporation subsidiaries: Deposition Technology (DepTec) and Likido, companies that focus on advancing precision microchip and semiconductor technologies and building energy-efficient commercial heat pumps and industrial chillers, respectively.
The Scotland facility is also expected to provide Dalrada Technology Ltd. with the ability to rapidly scale up production capabilities to meet the growing demand for the company’s innovative heat pumps, not just in the UK, but around the world as well.
“Our new facility will bring together our business units and allow us to continue delivering bold technology and clean energy solutions to the UK market and beyond,” said Brian Bonar, CEO and Founder of Dalrada Financial Corporation. “We believe this is the ideal location to suit the needs of our growing businesses,” he added.
Bill Bonar, CEO of Dalrada Technology Ltd., and Co-Founder of Deposition Technology Ltd. said of the new headquarters, “Incorporating DepTec and Likido into a single building will allow us to maximize our ability to innovate technology solutions in specific markets through the effective collaboration of the design and engineering teams from both subsidiaries. This also allows the company to reduce costs and reduce energy usage by moving both business units under a new roof.”
Dalrada Technology Ltd. Plans on being moved into the new facility and fully operational by March 1.
About Dalrada Financial Corporation
Dalrada Financial Corporation (OTCQB: DFCO) is a forward-facing organization that continually produces disruptive products and services that accelerate positive change for current and future generations.
Since 1982, Dalrada has redefined possibilities while boldly addressing global challenges with transformative innovations that drive targeted advances in emerging markets for a new era of human behavior and interaction, ensuring a bright future for the world around us.
Dalrada Financial Corporation is committed to positively impacting people, businesses, and the planet through sustainable solutions. For more information, please visit www.dalrada.com, and follow us on Twitter, Facebook, and LinkedIn.
About Dalrada Technology Ltd.
Dalrada Technology Ltd. is a wholly-owned subsidiary of Dalrada Financial Corporation. The company’s primary focus is advancing semiconductor technologies and delivering clean energy solutions through the companies Deposition Technology (DepTec) and Likido. Dalrada Technology Ltd. is also the proud sponsor of Greenock Morton Football Club, a Scottish Championship league team.
About Deposition Technology
Deposition Technology (DepTec) was founded in 2004 to provide refurbished physical vapor deposition (PVD) systems. Over the years, the company has developed re-manufacturing capabilities and robust upgrades to legacy systems to keep these systems in operation while updating them with the latest technology and advanced features.
In 2014, DepTec developed its own unique PVD system, the EVOS, and entered the OEM arena. The company now has multiple systems installed to assist in producing devices used in modern medical and communications products.
DepTec innovates with continuous R&D programs, developing the next generation of precision equipment and upgrades. Its new product, the EVOS CVD, for advanced chemical thin film production, will be available to the market soon. For more information, please visit www.deptec.com.
About Likido
Likido is developing true energy-efficient solutions for a Net Zero world by 2050. Delivering proprietary technology that significantly reduces harmful CO2 emissions, patent-pending Likido™ONE heat pumps represent the future of heating and cooling. These revolutionary machines are designed to capture and reuse thermal energy at a significant reduction in cost while aiding in the dramatic reduction of GWP (global warming potential). Likido proudly builds next-generation energy solutions that solve one of the world’s greatest challenges: the decarbonization of heat.
Likido is an international clean energy technology company with offices and manufacturing in Scotland; California; Malaysia; and other global locations.
Disclaimer
Statements in this press release are not historical facts. The statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.
Contacts
William Bonar (wbonar@dalrada.com)
DALRADA FINANCIAL CORPORATION
OTCQB:DFCO View stock quote and chart View SEC Filings
Release Summary
New UK-based facility will allow a specialized division of Dalrada Financial Corporation to further expand Deposition Technology (DepTec) and Likido.
More NewsRSS feed for Dalrada Financial Corporation
Contacts
William Bonar (wbonar@dalrada.com)
Registered office address
1 Kingsthorne Park, Houstoun Industrial Estate, Livingston, Scotland, EH54 5DB
Company status
Active
Company type
Private limited Company
Incorporated on
5 January 2016
Accounts
Next accounts made up to 30 June 2024
due by 31 March 2025
Last accounts made up to 30 June 2023
Confirmation statement
Next statement date 1 September 2024
due by 15 September 2024
Last statement dated 1 September 2023
Nature of business (SIC)
62012 - Business and domestic software development
DALRADA TECHNOLOGY LTD
Company number SC523533
Follow this company File for this company
CompanyOverviewfor DALRADA TECHNOLOGY LTD (SC523533)Filing historyfor DALRADA TECHNOLOGY LTD (SC523533)Peoplefor DALRADA TECHNOLOGY LTD (SC523533)Morefor DALRADA TECHNOLOGY LTD (SC523533)
OfficersPersons with significant control
Filter officers
Filter officersCurrent officers
Officers:6 officers / 3 resignations
BONAR, William Ian Martin
Correspondence address
1 Kingsthorne Park, Houstoun Industrial Estate, Livingston, Scotland, EH54 5DB
Role ACTIVE
Secretary
Appointed on
10 February 2023
BONAR, William Ian Martin
Correspondence address
Fairmont House, 21 Oakbank Park Way, Eh482tw, Livingston, West Lothian, Scotland, EH53 0TH
Role ACTIVE
Director
Date of birth
July 1971
Appointed on
5 January 2016
Nationality
British
Country of residence
Scotland
Occupation
Director
GOURDIE, Pauline
Correspondence address
1 Kingsthorne Park, Houstoun Industrial Estate, Livingston, Scotland, EH54 5DB
Role ACTIVE
Director
Date of birth
July 1971
Appointed on
9 December 2022
Nationality
British
Country of residence
United States
Occupation
Company Director
GOURDIE, Pauline
Correspondence address
Fairmont House, 21 Oakbank Park Way, Eh482tw, Livingston, West Lothian, Scotland, EH53 0TH
Role RESIGNED
Secretary
Appointed on
5 January 2016
Resigned on
8 September 2022
GOURDIE, Pauline
Correspondence address
Fairmont House, 21 Oakbank Park Way, Eh482tw, Livingston, West Lothian, Scotland, EH53 0TH
Role RESIGNED
Director
Date of birth
July 1971
Appointed on
5 January 2016
Resigned on
8 September 2022
Nationality
British
Country of residence
United States
Occupation
Director
MACKENZIE, Ian Robert
Correspondence address
Hollytrees, 2 Culver Park Close, Kingsbridge, Devon, England, TQ7 1LD
Role RESIGNED
Director
Date of birth
August 1968
Appointed on
9 June 2022
Resigned on
15 February 2023
Nationality
British
Country of residence
England
Occupation
Company Director
Even at a one time value of sales this stock should be around .40c to .60c its crazy
I hear that, but maybe this is where I'm confused about the daily volumes falling. It seems like, it wouldn't take too much volume to blow past the numbers... unless they are small volume short traders? I'd actually be curious if someone could help explain that aspect... looking at the level two's, it just seems like very little action, which confuses me since there seems to be more attention from some of the social platforms. I mean If I had an extra 10k sitting around to throw at this I would... I'm not sure what it will take to increase the buying pressure. I know I've said before I think positive cashflow, which seems to be where the company is headed will be the big catalyst.... but I'd have expected a bit more of a melt up. I mean, Like I said, I'm still buying, but basically being all in on the position at this point, for me I'm happy to continue to wait... Paytience right? But yeah, if someone could help me understand being caught by short traders, while there is very little volume, I'd be grateful for the education!
The most important thing to know about a BONAR stock is that it is not an "investment".
A great quote:
Ransom1
Re: None
Monday, December 24, 2018 4:04:18 PM
Post# 3229 of 26326
Best of luck you have been trying to pump this stock for almost a year now.Still below .o2 CENTS, The problem you have is this isnt a real company. Brian Bonar only know how to steel IRS MONEY.
Unfortunately we are in the grips of the short traders. The company needs to do something to squeeze them out, not sure what that is.
I know. Maybe people just watching? It'll be a FOMO for sure once it starts to move. I know I'm still adding! Things happened like they said, great Q! Strange volumes though!
Thanks for clearing this out...But I Don't know what will it take to move this stock again. Thought after the financial report then it will moved again but yet hardly any trading..Especially the doubled in revenue and cut the expenses down to 246k from 4mill... Any other stock this turtle would be trading $1 to $ 5 already or at least. 50 but yet can't even moved over .20... The longest drought this had been.. I think some of the old timer had left the building. I'm talking about those that invested since 2018 like me and did make a big money from .01s to .92 but I don't see any old timer anymore, maybe they just not posting anymore until the stock move again or they're all got tired of it. I'll wait for 1 more ye and see. Gl..
BONAR rips off ex partner and then tries to sue him...
EPIC FAIL !!!
https://dockets.justia.com/docket/california/casdce/3:2023cv01064/761054
There's more in the list, partial listing...
CAN ANY OF THIS B.S. be traced to a viable, functional business?
News Archive.
Dalrada Financial Corporation Files Form 10-Q, Announces Third Quarter Revenue of $10.3 Million
READ MORE
Dalrada Financial Corporation’s Wholly-Owned Subsidiary, Genefic, Inc. Announces New Telemedicine Services, Enters Booming Weight Loss Drug Market
READ MORE
Dalrada Financial Corporation Files Patent Application for Proprietary Technology that Creates Carbon Utility Tokens
READ MORE
Dalrada Financial Corporation Subsidiary, Dalrada Home Corp., forms Advisory Board and Announces Inaugural Members
READ MORE
Dalrada Financial Corporation Enters $104 Billion Carbon Credit Market with Data Mining Innovation
READ MORE
Dalrada Financial Corporation Announces Heat Pump Product Expansion, Enters Home and Residential Heat Pump Market
READ MORE
Dalrada Corporation Announces Authorized Share Reduction Highlighting Huge Growth Potential in 8-K Filing
READ MORE
Dalrada Financial Corporation Announces $4.5 Million in Cost-Cutting Reductions to Accelerate Path to Profitability
READ MORE
Shareholder Letter from Chairman and CEO, Brian Bonar
READ MORE
Dalrada Reports 54.3% Revenue Increase and Positive Net Equity in Annual 10-K
READ MORE
Dalrada Technology Spain Reaches Distribution Agreement with JBS Consulting to Build and Install up to 2,300 Heat Pumps
READ MORE
Dalrada Corporation Announces Further Global Expansion; Establishes Dalrada Technologies Morocco
READ MORE
Genefic’s Achieve Weight-Loss and Wellness Enjoys Impressive Showing at Pharmacy Profit Summit 2023
READ MORE
Dalrada’s Genefic Wellness Group Launches New Infusion Clinics to Deliver Successful Alternative Therapies
READ MORE
Dalrada’s Genefic Launches Achieve Weight-Loss and Wellness to Target Emerging Weight Loss Market
READ MORE
Dalrada’s Energy Services’ Subsidiary Licenses its Intellectual Property and Technical Knowledge to Pando Infrastructure
READ MORE
Dalrada Pharmaceutical Subsidiary, Watson Rx Solutions, Earns Prestigious NABP Specialty Pharmacy and Digital Pharmacy Accreditation
READ MORE
Dalrada Corporation Announces the Opening of its Heat Pump Showroom in Las Vegas
READ MORE
Dalrada Continues Corporate Restructuring Efforts with Streamlined Operations and Leadership to Improve Subsidiary Interaction and Reduce SG&A
READ MORE
Dalrada Corporation Announces Further European Expansion, Creates Dalrada Technology Spain, S.L.
READ MORE
Dalrada Executes Corporate Restructuring to Increase Focus on Core Climate Technologies Business and Reduce SG&A by Approximately $3 Million Annually
READ MORE
Watson Rx Solutions Earns Two Prestigious Pharmaceutical Accreditations from URAC
READ MORE
Dalrada Financial Corporation Reports Revenue of $9.5 Million, an Increase of over $4 Million or 80% During Q3 2023
READ MORE
Dalrada Corporation Streamlines Board of Directors to Reflect US and Global Expansion
READ MORE
Dalrada Energy Services Signs Agreement with AKF Group for Clean Energy Efficiency Building Projects with an Estimated Value of More than $10 Million Annually
READ MORE
Dalrada Corporation Appoints Brian Murphy to its Clean Energy Advisory Board
READ MORE
Genefic’s Watson Rx Solutions Earns Prestigious NABP Merchant Accreditation
READ MORE
Genefic Announces Opening of New Corporate Headquarters in Northern San Diego County
READ MORE
New York and Beyond: Phasing Out Fossil Fuel-Burning Furnaces
READ MORE
Dalrada’s Strong Revenue Generation Includes 23% Growth to $5.3 Million During the Second Quarter of Fiscal 2023
READ MORE
Dalrada Technology Ltd. Moves into New UK Headquarters Designated for Clean Energy Technology and Manufacturing
READ MORE
Dalrada Appoints Harvey Hershkowitz as Chairman and CEO of Genefic
READ MORE
Dalrada Health Unveils New Operating Structure to Support Significant Growth, Changes Name to Genefic
READ MORE
Dalrada Selects New Independent Auditor to Support Current Business Growth
READ MORE
Dalrada Health’s Empower Genomics Receives CDC Approval and Funding for Vaccine Initiative
READ MORE
Dalrada Reports Continued Growth with $4.3 Million Revenue During First Quarter 2023
READ MORE
Dalrada Reports Fiscal 2022 Results, Continues Strong Upward Trajectory in All Four Core Segments
READ MORE
University of Arkansas Contracts Dalrada Corporation’s Deposition Technology Ltd. to Build a Plasma Enhanced Chemical Vapor Deposition Tool
READ MORE
Dalrada Corporation Acquires Bothof Brothers Construction
READ MORE
Dalrada Corporation Announces Delay in Annual Report on Form 10-K
READ MORE
Dalrada Corporation Partners with Averett University to Drive Campus-Wide Green Energy Initiatives
READ MORE
Dalrada Corporation appoints Anuradha Biswas to Board of Directors
READ MORE
Abhik Biswas, CTO of Prakat Solutions, Recently Accepted into Forbes Technology Council
READ MORE
Dalrada Health expands wellness services to support local athletes and fans
READ MORE
Dalrada Corporation Appoints Heather McMahon to the Dalrada Clean Energy Advisory Board
READ MORE
Dalrada Health Advisory Board expands to support business growth
READ MORE
Dalrada Energy Services announces partnership with Banyan Infrastructure to improve ESG banking transparency
They still use an auditor. Q’s are reviewed and the K is audited, the next audit will be after June which is there year end. The CEO has stated they will reach profitability by calendar year end and they are certainly headed in that direction, when that happens this stock will move big IMHO.
I am too because if I sell then probably it will drag this to low .08 area.. because I am loaded to.my eyes balls average. 08s.. One question is why Dfco no longer used financial auditor because the report said unaudited financial report, we need that without it investors do not trusted those numbers. ..
I am continuing to hold and am happy with the progress which is in line with the CEO predictions.
LOL!!!! I'm up 291% today on my only penny.....
It's about the tech and quality of management, or in the case of DFCO the lack of same, not the OTC.
Its not DFCO specific its the whole OTC market..The crypto market is where all the risk capital is playing right now. The crypto market is the new OTC market of the early 2000s
What do you expect from a stock with BRIAN BONAR'S track record?
He's been ripping off stockholders since the '80's.
Not even surprised that this stock didn't move even given doubled in revenue and reduced expenses from some 4mill down to 246k only. I don't even know what will move this turtle anymore...Scratching my head , gotten so much shares in my holding..
Does anyone really think it's ethical for the CEO of a "public" company (even if it is an OTC penny) to buy out a private company that his family owns? They profit by the buy out that is 100% financed on the OTC.
Totally shady, IMO.
See replied to post for a sample of BONAR's MOA.....
Genific gibberish...
The truth is they have one pharmacy and no unique business plan.
Conclusion
As technology and health advancements continue to evolve, local pharmacies are emerging as vital hubs for providing personalized healthcare services to their communities. This transformation enhances patient outcomes and strengthens the pharmacist-patient relationship, ensuring that each individual receives the care and attention they deserve.
Personalized healthcare is no longer a distant dream; it’s a reality that is unfolding in local pharmacies worldwide. Through integrating technology, implementing health advancements, and committing to patient-centric care, local pharmacies are becoming beacons of personalized healthcare, empowering individuals to take charge of their well-being like never before.
Overview.
Genefic is a wholly-owned subsidiary of Dalrada Financial Corporation (OTCQB: DFCO).
For years, Genefic has focused on building end-to-end, comprehensive health solutions. We understand that a person’s health is not a singular issue or event, nor is it confined to just one aspect.
The company believes in providing total health care solutions for improved health and wellness, including specialty pharmacy services that promote healing, recovery, and an overall better quality of life. Genefic means high-quality research and development, innovation, and access that ultimately delivers better health outcomes.
The leadership team at Genefic and Genefic Specialty Pharmacy is comprised of dedicated professionals with vast experience: accomplished scientists, university professors, board-certified surgeons, doctors, and other esteemed medical staff, whose primary focus is creating healthy environments and increasing quality of life and improving health outcomes for people around the wor
In the ever-evolving field of healthcare, one of the most promising and transformative trends is the move toward personalized care through advancements made in technology. Local pharmacies are now emerging as key players in this major shift. towards tailored, patient-centric healthcare. In this blog post, we will explore how technology and health advancements are revolutionizing healthcare at local pharmacies, making it more personalized than ever before.
1. Digital Health Records and EHR Integration
Local pharmacies are moving away from traditional paper-based records and embracing digital health records. Electronic Health Record (EHR) systems are becoming more prevalent, allowing pharmacists to access a patient’s medical history quickly and easily. This integration enables pharmacists to provide medication recommendations and advice tailored to each patient’s unique health profile, reducing the risk of adverse drug interactions and ensuring medication adherence.
2. Medication Adherence Apps
Mobile applications are changing the game when it comes to medication adherence. Many local pharmacies now offer personalized apps that remind patients to take their medications on time, provide information about potential side effects, and offer convenient prescription refills. These apps empower patients to take control of their health while receiving guidance from their pharmacists.
3. Pharmacogenomics
Advancements in pharmacogenomics are enabling pharmacists to customize medication regimens based on a patient’s unique genetic makeup. By analyzing an individual’s genetic profile, pharmacists can identify how their body metabolizes certain drugs and adjust prescriptions accordingly. This personalized approach minimizes trial and error by finding the most effective and safe medications for each patient.
4. Telehealth Services
Telehealth and “telepharmacy” services have gained immense popularity, especially in remote areas where access to healthcare is limited. Through video consultations and virtual pharmacies, patients can consult with pharmacists from the comfort of their homes, receiving personalized advice and prescription recommendations without the need for a physical visit.
5. Medication Synchronization Programs
Local pharmacies are introducing medication synchronization programs, which allow patients to align all their prescription refills to a single, convenient date. Reducing the chances of missed doses simplifies medication management and improves overall patient satisfaction.
6. Health Monitoring Devices
Technological advancements have given rise to various health monitoring devices, such as wearable fitness trackers and smart scales. Local pharmacies are incorporating these tools into their personalized healthcare offerings as well. Pharmacists can monitor and analyze patients’ health data, guiding how to make lifestyle changes that promote better health outcomes.
7. Preventive Services
Beyond medication management, local pharmacies are expanding their services to include preventive healthcare. From offering vaccinations to conducting health screenings, pharmacies are quickly becoming holistic healthcare hubs focusing on keeping patients healthy and informed.
Conclusion
As technology and health advancements continue to evolve, local pharmacies are emerging as vital hubs for providing personalized healthcare services to their communities. This transformation enhances patient outcomes and strengthens the pharmacist-patient relationship, ensuring that each individual receives the care and attention they deserve.
Personalized healthcare is no longer a distant dream; it’s a reality that is unfolding in local pharmacies worldwide. Through integrating technology, implementing health advancements, and committing to patient-centric care, local pharmacies are becoming beacons of personalized healthcare, empowering individuals to take charge of their well-being like never before.
Pharmacies’ Roles in Dispensing Specialty Drugs
Over the past decade, more pharmaceuticals have been classified as specialty drugs.15 Specialty drugs are very expensive drugs, with a course of treatment in 2015 averaging $52,486.16 In 2019, only 4.9 percent of commercially insured patients took specialty drugs, but they were responsible for half of the total drug spend.17 Specialty drugs are also often complex biologic products, which may require special storage and additional training for pharmacists.
In response to the growth in specialty drugs, a niche type of pharmacy known as a specialty pharmacy has emerged. In 2018, 900 pharmacies in the U.S. had specialty accreditation.18 Specialty pharmacies operate separately from most retail pharmacies and are primarily owned and operated by PBMs, wholesalers, providers, or integrated delivery networks, though there are still some independent and small regional specialty pharmacies. Use of specialty pharmacies has been associated with higher rates of adherence than use of retail pharmacies for specialty drugs.
The large chain pharmacies such as CVS and Walgreens have been able to diversify to own both specialty and retail pharmacies, enabling them to create new integrated models aimed at improving medication adherence and other measures of clinical performance. For example, while most specialty pharmacies ship the drugs to patients, CVS’s “specialty at retail” model allows patients to access specialty drug patient management programs while picking up their specialty and traditional drugs at one location.19
Though quality is frequently used as a rationale for involving specialty pharmacies, it is difficult to determine the extent to which quality differs between specialty pharmacies and traditional retail pharmacies. Specialty pharmacies also may exacerbate drug spending if their prices are higher than those at retail pharmacies. There is little evidence on the extent of price competition within the specialty pharmacy sector and between specialty pharmacies, retail chain pharmacies, and independents. With specialty drugs driving growth in pharmaceutical spending, it will become increasingly important to ensure that as specialty drugs go off patent, the pharmacies selling them operate in a competitive environment that delivers the best quality at the lowest cost. More research will be needed to understand the impact that different pharmacy channels have on the cost and outcomes of these medications.
If DFCO pops it will poop afterward...
There are no fundamentals here. No unique IP or patents in any of their so-called divisions...
The rest of the story on "DepTec"
It was acquired from BONAR and his family. I'm sure they will use DFCO funds to build up the business and pay themselves wages, then when the stock goes bust they will repo the busiess.
Year Ended Jun 2023
Total Assets £783.29k
-£127.29k (-13.98%)
vs previous year
Total Liabilities
£-686.36k
-£128.6k (-23.06%)
vs previous year
Net Assets
£96.93k
-£255.89k (-72.53%)
vs previous year
Cash in Bank
£29.65k
-£152.42k (-83.72%)
vs previous year
Employees
8
+1 (+14.29%)
vs previous year
Turnover
Unreported
Debt Ratio (%)
87.63%
+26.38 (+43.07%)
vs previous year
Tomorrow will be the day that this OTC pops!
DFCO's Genfic did $8.6 million in revenue thats up $4.2 million from the previous quarter its doubling every Q.....Accounts payable and Liabilities went from 5mil in Q2 to now 254,00$ thats great.... Genefic revenue:
▪ $8.6 million
▪ Up $4.2 million (95.5%) from previous quarter
▪ Up $3.8 million (80.1% increase from Q3 2023)
What investors are missing is DFCO has many revenue models not just heat pumps. We have the commercial and residential heat pumps, Genfic and I also saw in the Q Dep-Tec...Deposition Technologies (“DepTec”) - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.
What we need to realize is that these revenues are from new initiatives as prior revenues were all covid based. These guys are sure getting it turned around. The expense reduction is the most impressive and the net equity is growing. Way to go DFCO.
Financial are out and look DAMN good! - Q profits doubled y/y - revenues up, expenses way down - all heading in the right direction - looks pretty clear $DFCO will turn a profit this year as they stated!
https://www.otcmarkets.com/filing/html?id=17535715&guid=RrQ-k619PyECJth
Pre - Market reaction seems to like it too!
Hope the financial report comes out tomorrow, we need to.make a big long over due run.
Daily trading stats say this post is nonsense:
some action today compared to the past couple weeks!!!!
05/13/24 0.197 0.197 0.186 0.1959 26.959
05/10/24 0.1899 0.197 0.1899 0.197 6,189
05/09/24 0.197 0.197 0.19 0.19 30,328
05/08/24 0.186 0.19 0.186 0.19 6,120
05/07/24 0.181 0.19 0.181 0.19 1,178
05/06/24 0.1906 0.1906 0.1846 0.1846 10,240
05/03/24 0.1945 0.1962 0.185 0.185 26,204
05/02/24 0.196 0.1965 0.189 0.195 12,916
05/01/24 0.1928 0.1997 0.1928 0.1997 7,113
04/30/24 0.188 0.20 0.188 0.1969 53,295
04/29/24 0.19 0.20 0.188 0.1922 71,491
04/26/24 0.1972 0.1972 0.1853 0.188 170,059
04/25/24 0.209 0.209 0.192 0.1965 67,591
04/24/24 0.209 0.209 0.202 0.2089 45,395
04/23/24 0.2248 0.2262 0.19 0.19 168,402
04/22/24 0.235 0.235 0.225 0.2256 92,837
04/19/24 0.235 0.235 0.225 0.23 48,663
04/18/24 0.235 0.235 0.222 0.2325 25,145
04/17/24 0.235 0.235 0.221 0.2298 45,839
04/16/24 0.2257 0.235 0.2201 0.228 41,313
04/15/24 0.22 0.23 0.20 0.23 105,216
04/12/24 0.195 0.234 0.195 0.224 109,015
04/11/24 0.24 0.24 0.1902 0.2095 409,137
04/10/24 0.20 0.234 0.20 0.225 164,323
04/09/24 0.20 0.219 0.185 0.2114 105,197
04/08/24 0.16 0.22 0.16 0.20 466,217
04/05/24 0.165 0.165 0.152 0.1565 106,965
04/04/24 0.155 0.1697 0.1538 0.1665 218,343
04/03/24 0.1599 0.1599 0.15 0.1549 289,496
04/02/24 0.15 0.1599 0.15 0.1583 59,501
04/01/24 0.1519 0.154 0.143 0.1528 53,091
some action today compared to the past couple weeks!!!!
I hope we double thw revenue and raises the guidance.
DFCO has never been headed anywhere other than BONAR's special place in purgatory,
The Q should be filed this week and that will tell where we are headed
Let's get this beast going...Been long enough.
DFCO
https://dalrada.com/
Updated May 2021:
Dalrada Financial was a defunct organization up until January 2018 when out of the blue it began filing again with OTCMarkets.com (up to date). At this point the market got excited and repriced shares from the low .00s up to the .02 range (give or take a penny), where it sat for a solid year with a slow sprinkling of company updates periodically. Ever since that breakout event in January 2018 the stock has exploded to almost $0.50 a share, 14 year high, where it is currently basing for another leg up. Despite having little interest from traders since the initial explosive blip in early 2018, the stock has held its gains amazingly well. We've seen nearly 3 years of updates now as the company went from defunct to having multiple subsidiaries under it's umbrella, multiple acquisitions (very favorable terms for relatively small amounts of restricted common shares, mind you), filing with the SEC(!), and numerous fundamental catalysts on deck (see below press releases). $DFCO is grossly mispriced, but that will change in a hurry when the switch is flipped here. They recently reported a 3,181% Increase In Quarterly Financial Results! Check out what this sleeping giant is up to.
DALRADA FINANCIAL “DFCO”
Publicly-traded on the OTCQB under the symbol “DFCO”, Dalrada and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. The team is dedicated to scaling and accelerating business growth through exceptional financial planning, risk and business analysis, advanced technology platforms, branding, sales and marketing, human resources, legal, accounting, and administrative support.
Dalrada solves real-world problems by producing innovation-focused and technologically-centered solutions on a global level.
Delivering next-generation manufacturing and healthcare products and services that provide and propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital.
OUR BUSINESSES (3 VERTICLES):
DALRADA PRECISION
Dalrada Precision provides alternative solutions to OEMs through design and manufacturing of component parts that are customized for any specific solution.
The company also produces heater/chiller units that provide simultaneous heating and cooling, without the need for combustion or the burning of fossil fuels, through its wholly-owned company, Likido.
www.dalradaprecision.com
www.likido.net
DALRADA TECHNOLOGY
Through its technology division, Prakat Solutions, the company brings over 10 years of expertise providing end to end product engineering services across various domains, including – Banking & Financial Services, Telecom, Retail, Healthcare, Manufacturing, Legal and IT Infrastructure.
DALRADA HEALTH PRODUCTS
Dalrada Health is in the business of solving health problems – globally. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health is able to reach underserved markets through strong partnerships and the development of efficient supply chains.
www.glanhealth.com
The CDC has recommended caution with sanitizers and the product can be toxic if over used.
www.pacificstemcells.com
Pacific Stem Cells Web site lists no medical professional.
www.ihgcc.com
This company trains CNAs and is apparently not active at this time due to covid, 2 of 3 locations shut down.
NEWS/PRESS RELEASE HISTORY:
https://finance.yahoo.com/quote/DFCO/press-releases/
RECENT PRESS RELEASE HIGHLIGHTS:
Dalrada Financial Corporation Announces Up List To OTCQB Market
https://finance.yahoo.com/news/dalrada-financial-corporation-announces-list-130000244.html
Dalrada Reports 3,181% Increase In Quarterly Financial Results
https://finance.yahoo.com/news/dalrada-reports-3-181-increase-130000960.html
Dalrada Financial Corp Records First Sales of LikidoVOLT® Independent Power Generators With Hidden Villa Ranch
https://finance.yahoo.com/news/dalrada-financial-corp-records-first-120000713.html
Prakat and Dragonchain Partner to Create Clean Energy, Fintech, and Healthcare Blockchain Solutions
https://finance.yahoo.com/news/prakat-dragonchain-partner-create-clean-165500113.html
Dalrada Launches Development of Likido®HOME Water Heater Designed to Improve Energy Efficiency by 300% and Significantly Reduce Carbon Emissions
https://finance.yahoo.com/news/dalrada-launches-development-likido-home-133000775.html
Dalrada Financial Corporation Launches LikidoVOLT® Independent Power Generators With 90% Clean Energy Efficiency Range
https://finance.yahoo.com/news/dalrada-financial-corporation-launches-likidovolt-130000998.html
Dalrada Executes Contract For Likido North America Exclusive Manufacturing With Tongrun International
https://finance.yahoo.com/news/dalrada-executes-contract-likido-north-203000292.html
Dalrada Precision Acquires Green Energy License For 87% Energy Efficiency And Cost-Savings Advancing Subsidiary Abilities
https://finance.yahoo.com/news/dalrada-precision-acquires-green-energy-120000817.html
DFCO'S Likido Limited Awarded Clean Energy Grant By Innovate UK, Aligns With CLIMAGAL S.L. For Europe Climate Change Implementation
https://finance.yahoo.com/news/dfcos-likido-limited-awarded-clean-130000069.html
Dalrada Health Presents VIA Cervical Cancer Screening Study Findings at 17th World Congress for Cervical Pathology and Colposcopy
https://finance.yahoo.com/news/dalrada-health-presents-via-cervical-120000323.html
Dalrada Financial Corporation Aids COVID-19 Vaccination Administration With Healthcare Staff Of Newly Acquired International Healthcare Group (IHG)
https://finance.yahoo.com/news/dalrada-financial-corporation-aids-covid-130000621.html
https://www.facebook.com/dalrada
https://twitter.com/dalrada_DFCO
DFCO
https://dalrada.com/
09/06/2023 BONAR's Dalrada hasn't sold a single heat pump....
There are no spec sheets so you can't compare them to the long established companies they are competing with.
Crown Glory Holding seems to be a dummy shell...
See screen shot below at https://crowngloryholding.com/about-us/
Crown Glory Holding seems to be a dummy shell...
See screen shot above has been "fixed" with some mediocre text but https://crowngloryholding.com/about-us/ on September 6. They've added a couple paragraphs of blah blah blah
But the site is still dummied up... this is from today 10/20/23:
DALRADA NASDAQ BOUND!
Along with the recent organizational restructuring, our Board of Directors is taking the necessary steps to make Dalrada compliant with NASDAQ requirements. Once compliant, this will also allow the company to qualify for other national and global exchanges once we have satisfied all other listing requirements.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |